Shanghai RAAS Blood Products (002252.SZ) controlling shareholder Haiyingkang plans to invest 250 million to 500 million yuan to increase its holdings.

Shanghai RAAS Blood Products (002252.SZ) announced that the company's controlling shareholder, Haiyingkang (Qingdao) Medical Technology Co., Ltd. (referred to as "Haiyingkang"), plans to increase its holdings of the company's shares within 6 months from the date of this announcement. The total amount of this planned increase is not less than 2.5 billion yuan, and not more than 5 billion yuan (including this amount and excluding transaction costs).